Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
85.8M
-
Shares change
-
-2.26M
-
Total reported value, excl. options
-
$1.28B
-
Value change
-
-$105M
-
Put/Call ratio
-
0.63
-
Number of buys
-
97
-
Number of sells
-
-71
-
Price
-
$14.92
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2021
207 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q4 2021.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 85.8M shares
of 226M outstanding shares and own 37.93% of the company stock.
Largest 10 shareholders include TPG GP A, LLC (18.7M shares), VANGUARD GROUP INC (6.74M shares), BlackRock Inc. (6.53M shares), PRIMECAP MANAGEMENT CO/CA/ (4.66M shares), STATE STREET CORP (4.41M shares), JPMORGAN CHASE & CO (3.62M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.25M shares), Casdin Capital, LLC (2.65M shares), CITADEL ADVISORS LLC (2.37M shares), and FMR LLC (1.88M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.